1. Home
  2. NRIX
  3. NRIX News

Latest Nurix Therapeutics Inc. Common stock (NRIX) News on December 22, 2024

NRIX

MT Newswires

3 days ago

Nurix Therapeutics Says Waldenstrom Macroglobulinemia Drug Granted Fast Track Designation by FDA

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia
NRIX

GlobeNewswire

3 days ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers?
NRIX

Insider Monkey

11 days ago

Is Nurix Therapeutics (NRIX) the Worst ARK Stock to Buy According to Short Sellers?

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting
NRIX

GlobeNewswire

13 days ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

NRIX

MT Newswires

16 days ago

BMO Capital Initiates Nurix Therapeutics at Outperform With $35 Price Target

Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
NRIX

Insider Monkey

18 days ago

Why Is Nurix Therapeutics, Inc. (NRIX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting
NRIX

GlobeNewswire

20 days ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
NRIX

GlobeNewswire

a month ago

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

NRIX

MT Newswires

a month ago

Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
NRIX

GlobeNewswire

a month ago

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024
NRIX

GlobeNewswire

a month ago

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
NRIX

GlobeNewswire

2 months ago

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics to Participate in Upcoming Investor Conferences
NRIX

GlobeNewswire

2 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

NRIX

MT Newswires

2 months ago

UBS Initiates Nurix Therapeutics With Buy Rating, $35 Price Target

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit
NRIX

GlobeNewswire

2 months ago

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial
NRIX

Clinical Trials Arena

2 months ago

Nurix Therapeutics’ NX-5948 shows promise in Waldenstrom’s macroglobulinaemia trial

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
NRIX

GlobeNewswire

2 months ago

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur
NRIX

GlobeNewswire

2 months ago

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

NRIX

MT Newswires

2 months ago

RBC Trims Price Target on Nurix Therapeutics to $26 From $27, Keeps Outperform, Speculative Risk

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates
NRIX

Zacks

2 months ago

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates

NRIX

MT Newswires

2 months ago

Nurix Therapeutics Fiscal Q3 Net Loss Narrows, Revenue Falls

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
NRIX

GlobeNewswire

2 months ago

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

NRIX

MT Newswires

2 months ago

Jefferies Initiates Coverage on Nurix Therapeutics With Buy Rating, $41 Price Target

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
NRIX

GlobeNewswire

2 months ago

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

Nurix Therapeutics Announces Presentations at Discovery on Target Conference
NRIX

GlobeNewswire

3 months ago

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
NRIX

GlobeNewswire

4 months ago

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

Nurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right Now
NRIX

Insider Monkey

4 months ago

Nurix Therapeutics, Inc. (NRIX): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Nurix Therapeutics to Participate in Upcoming Investor Conferences
NRIX

GlobeNewswire

4 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)
NRIX

GuruFocus.com

4 months ago

Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)

NRIX

MT Newswires

4 months ago

Nurix Therapeutics Insider Sold Shares Worth $504,370, According to a Recent SEC Filing

NRIX

MT Newswires

4 months ago

Oppenheimer Adjusts Nurix Therapeutics Price Target to $27 From $25

We're Not Very Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
NRIX

Simply Wall St.

4 months ago

We're Not Very Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%
NRIX

Zacks

5 months ago

How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%

Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice
NRIX

Zacks

5 months ago

Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice

NRIX

MT Newswires

5 months ago

Barclays Adjusts Price Target on Nurix Therapeutics to $31 From $20, Maintains Overweight Rating

NRIX

MT Newswires

5 months ago

JPMorgan Adjusts Price Target on Nurix Therapeutics to $34 From $31, Maintains Overweight Rating

NRIX

MT Newswires

5 months ago

Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating

NRIX

MT Newswires

5 months ago

RBC Lifts Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
NRIX

Zacks

5 months ago

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

NRIX

MT Newswires

5 months ago

Nurix Therapeutics Q2 Loss Widens Amid Revenue Decline

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
NRIX

GlobeNewswire

5 months ago

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
NRIX

GlobeNewswire

5 months ago

Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a favorite amongst institutional investors who own 66%
NRIX

Simply Wall St.

6 months ago

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a favorite amongst institutional investors who own 66%

NRIX

MT Newswires

6 months ago

RBC Raises Price Target on Nurix Therapeutics to $26 From $23, Maintains Outperform, Speculative Risk

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
NRIX

Zacks

6 months ago

Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates

Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)
NRIX

GuruFocus.com

6 months ago

Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)

NRIX

MT Newswires

6 months ago

Nurix Therapeutics Insider Sold Shares Worth $400,216, According to a Recent SEC Filing

Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
NRIX

Zacks

6 months ago

Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?

NRIX

MT Newswires

6 months ago

HC Wainwright Raises Price Target on Nurix Therapeutics to $26 From $19, Maintains Buy Rating

Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment
NRIX

Investor's Business Daily

6 months ago

Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment

NRIX

MT Newswires

6 months ago

JPMorgan Adjusts Price Target on Nurix Therapeutics to $31 From $30, Maintains Overweight Rating

NRIX

MT Newswires

6 months ago

Sector Update: Health Care

NRIX

MT Newswires

6 months ago

Top Premarket Gainers

NRIX

MT Newswires

6 months ago

Nurix Therapeutics Says Patients Respond Well to Potential Non-Hodgkin Lymphoma Treatment in Phase 1 Trial

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
NRIX

GlobeNewswire

6 months ago

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

NRIX

MT Newswires

6 months ago

Nurix Therapeutics Files Mixed Shelf Registration

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
NRIX

GlobeNewswire

6 months ago

Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
NRIX

GlobeNewswire

7 months ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
NRIX

GlobeNewswire

7 months ago

Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer

NRIX

MT Newswires

7 months ago

Nurix Therapeutics Names New Board Chair

Nurix Therapeutics Announces Board Chair Transition
NRIX

GlobeNewswire

7 months ago

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?
NRIX

Zacks

7 months ago

Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
NRIX

GlobeNewswire

7 months ago

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

NRIX

MT Newswires

7 months ago

Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
NRIX

Zacks

8 months ago

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Nurix Therapeutics Announces Proposed Public Offering
NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics Announces Proposed Public Offering

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
NRIX

Zacks

8 months ago

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
NRIX

Zacks

8 months ago

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study

Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024
NRIX

GuruFocus.com

8 months ago

Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
NRIX

Zacks

8 months ago

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
NRIX

GlobeNewswire

8 months ago

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?
NRIX

Zacks

9 months ago

Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?

Nurix Therapeutics to Participate in Upcoming Investor Conferences
NRIX

GlobeNewswire

9 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
NRIX

GlobeNewswire

9 months ago

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
NRIX

GlobeNewswire

9 months ago

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
NRIX

GlobeNewswire

9 months ago

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial
NRIX

GlobeNewswire

9 months ago

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial

Nurix Therapeutics to Participate in Upcoming Investor Conferences
NRIX

GlobeNewswire

10 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
NRIX

GlobeNewswire

10 months ago

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting

Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?
NRIX

Zacks

10 months ago

Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?

Nurix Therapeutics Full Year 2023 Earnings: Misses Expectations
NRIX

Simply Wall St.

10 months ago

Nurix Therapeutics Full Year 2023 Earnings: Misses Expectations

Nurix Therapeutics Inc (NRIX) Reports Robust Year-End Financials and Clinical Progress
NRIX

GuruFocus.com

10 months ago

Nurix Therapeutics Inc (NRIX) Reports Robust Year-End Financials and Clinical Progress

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates
NRIX

Zacks

10 months ago

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
NRIX

GlobeNewswire

10 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NRIX

Zacks

a year ago

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
NRIX

GlobeNewswire

a year ago

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
NRIX

Zacks

a year ago

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

NETGEAR (NTGR) Reports Q4 Preliminary Results, Stock Up 2%
NRIX

Zacks

a year ago

NETGEAR (NTGR) Reports Q4 Preliminary Results, Stock Up 2%

Blend Labs, Inc. (NYSE:BLND) surges 13%; retail investors who own 45% shares profited along with institutions
NRIX

Simply Wall St.

a year ago

Blend Labs, Inc. (NYSE:BLND) surges 13%; retail investors who own 45% shares profited along with institutions

Carrols Restaurant Group (TAST) Rises Yet Lags Behind Market: Some Facts Worth Knowing
NRIX

Zacks

a year ago

Carrols Restaurant Group (TAST) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Clean Energy to Report Fourth Quarter 2023 Financial Results on February 27; Conference Call to Follow at 1:30 p.m. Pacific Time
NRIX

Business Wire

a year ago

Clean Energy to Report Fourth Quarter 2023 Financial Results on February 27; Conference Call to Follow at 1:30 p.m. Pacific Time

Are Investors Undervaluing North American Construction Group (NOA) Right Now?
NRIX

Zacks

a year ago

Are Investors Undervaluing North American Construction Group (NOA) Right Now?

Truist upgrades Sunnova, Enphase on global energy trends
NRIX

Yahoo Finance Video

a year ago

Truist upgrades Sunnova, Enphase on global energy trends

Aspen Aerogels, Inc. Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call
NRIX

PR Newswire

a year ago

Aspen Aerogels, Inc. Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call

Zacks Value Investor Highlights: Potbelly, Xperi, Virco, Enviri and Anywhere Real Estate
NRIX

Zacks

a year ago

Zacks Value Investor Highlights: Potbelly, Xperi, Virco, Enviri and Anywhere Real Estate

Share on Social Networks: